Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Guohua Yu

Showing results (211-220 of 237) with videos related to

Pageof 24
Sort By:
Frontiers in Oncology|February 11, 2025
Multi-institutional evaluation comparing guidance from International Ki67 Working Group vs National Health Commission of China on immunohistochemistry-based Ki67 assessment alongside the Quantitative Dot Blot methodYin Wang, Jiarui Zou, Qinghua Cao, et al.
Molecular Cancer|June 23, 2023
m<sup>6</sup>A methylation reader IGF2BP2 activates endothelial cells to promote angiogenesis and metastasis of lung adenocarcinomaHan Fang, Qi Sun, Jin Zhou, et al.
Nature Medicine|April 16, 2024
Prediction of tumor origin in cancers of unknown primary origin with cytology-based deep learningFei Tian, Dong Liu, Na Wei, et al.
The Lancet. Respiratory Medicine|December 7, 2025
First-line serplulimab plus chemotherapy with or without HLX04 versus chemotherapy in locally advanced or metastatic non-squamous non-small-cell lung cancer (ASTRUM-002): a randomised, double-blind, multicentre phase 3 trialLin Wang, Xuezhi Hao, Yanrong Hao, et al.
Ebiomedicine|January 13, 2024
Efficacy, safety and genomic analysis of SCT200, an anti-EGFR monoclonal antibody, in patients with fluorouracil, irinotecan and oxaliplatin refractory RAS and BRAF wild-type metastatic colorectal cancer: a phase Ⅱ studyLin Yang, Wen Zhang, Nanfeng Fan, et al.
Frontiers in Oncology|July 25, 2022
Penpulimab for Relapsed or Refractory Classical Hodgkin Lymphoma: A Multicenter, Single-Arm, Pivotal Phase I/II Trial (AK105-201)Yuqin Song, Keshu Zhou, Chuan Jin, et al.
Cancer Communications (London, England)|June 12, 2026
Serplulimab Plus Chemotherapy, with or without HLX04, versus Chemotherapy as First-Line Treatment for Nonsquamous NSCLC: Final Survival Analysis of the Phase III ASTRUM-002 StudyXuezhi Hao, Lin Wang, Yanrong Hao, et al.
The Lancet. Oncology|May 16, 2022
Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trialJie Wang, Caicun Zhou, Wenxiu Yao, et al.
Signal Transduction and Targeted Therapy|January 12, 2025
A multicenter, randomized, double-blind, placebo-controlled phase 3 study of Socazolimab or placebo combined with carboplatin and etoposide in the first-line treatment of extensive-stage small cell lung cancerZhiwei Chen, Jianhua Chen, Dingzhi Huang, et al.
Journal of Hematology & Oncology|June 6, 2025
Results of a phase 1/2 study of sacituzumab tirumotecan in patients with unresectable locally advanced or metastatic solid tumors refractory to standard therapiesQuchang Ouyang, Jordi Rodon, Yan Liang, et al.
Pageof 24

Showing results (211-220 of 237) with videos related to

Sort By:
Pageof 24
Frontiers in Oncology|February 11, 2025
Multi-institutional evaluation comparing guidance from International Ki67 Working Group vs National Health Commission of China on immunohistochemistry-based Ki67 assessment alongside the Quantitative Dot Blot methodYin Wang, Jiarui Zou, Qinghua Cao, et al.
Molecular Cancer|June 23, 2023
m<sup>6</sup>A methylation reader IGF2BP2 activates endothelial cells to promote angiogenesis and metastasis of lung adenocarcinomaHan Fang, Qi Sun, Jin Zhou, et al.
Nature Medicine|April 16, 2024
Prediction of tumor origin in cancers of unknown primary origin with cytology-based deep learningFei Tian, Dong Liu, Na Wei, et al.
The Lancet. Respiratory Medicine|December 7, 2025
First-line serplulimab plus chemotherapy with or without HLX04 versus chemotherapy in locally advanced or metastatic non-squamous non-small-cell lung cancer (ASTRUM-002): a randomised, double-blind, multicentre phase 3 trialLin Wang, Xuezhi Hao, Yanrong Hao, et al.
Ebiomedicine|January 13, 2024
Efficacy, safety and genomic analysis of SCT200, an anti-EGFR monoclonal antibody, in patients with fluorouracil, irinotecan and oxaliplatin refractory RAS and BRAF wild-type metastatic colorectal cancer: a phase Ⅱ studyLin Yang, Wen Zhang, Nanfeng Fan, et al.
Frontiers in Oncology|July 25, 2022
Penpulimab for Relapsed or Refractory Classical Hodgkin Lymphoma: A Multicenter, Single-Arm, Pivotal Phase I/II Trial (AK105-201)Yuqin Song, Keshu Zhou, Chuan Jin, et al.
Cancer Communications (London, England)|June 12, 2026
Serplulimab Plus Chemotherapy, with or without HLX04, versus Chemotherapy as First-Line Treatment for Nonsquamous NSCLC: Final Survival Analysis of the Phase III ASTRUM-002 StudyXuezhi Hao, Lin Wang, Yanrong Hao, et al.
The Lancet. Oncology|May 16, 2022
Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trialJie Wang, Caicun Zhou, Wenxiu Yao, et al.
Signal Transduction and Targeted Therapy|January 12, 2025
A multicenter, randomized, double-blind, placebo-controlled phase 3 study of Socazolimab or placebo combined with carboplatin and etoposide in the first-line treatment of extensive-stage small cell lung cancerZhiwei Chen, Jianhua Chen, Dingzhi Huang, et al.
Journal of Hematology & Oncology|June 6, 2025
Results of a phase 1/2 study of sacituzumab tirumotecan in patients with unresectable locally advanced or metastatic solid tumors refractory to standard therapiesQuchang Ouyang, Jordi Rodon, Yan Liang, et al.
Pageof 24